HQL-79

• Description :

  HQL-79, a potent, selective and orally active human hematopoietic prostaglandin D synthase (H-PGDS) inhibitor, highly selectively inhibits the synthesis of PGD2, and acts as an anti-allergic agent, with a Kd of 0.8 μM and an IC50 of 6 μM. Shows no obvious effect on COX-1, COX-2, m-PGES, or L-PGDS[1].

• UNSPSC :

  12352005

• Target :

  PGE synthase

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/hql-79.html

• Purity :

  99.89

• Solubility :

  DMSO : 2 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  N1(CCCC2=NN=NN2)CCC(OC(C3=CC=CC=C3)C4=CC=CC=C4)CC1

• Molecular Formula :

  C22H27N5O

• Molecular Weight :

  377.48

• References & Citations :

  [1]Aritake K, et al. Structural and functional characterization of HQL-79, an orally selective inhibitor of human hematopoietic prostaglandin D synthase. J Biol Chem. 2006 Jun 2;281 (22) :15277-86. Epub 2006 Mar 17.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [162641-16-9]